In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
How to Find a Cancer Treatment Trial
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
Featured Clinical Trials Supported by NCI

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 32 for your search:

Drug:  MART-1 antigen
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Vaccine Therapy and/or Sargramostim in Treating Patients With Locally Advanced or Metastatic Melanoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067568, U10CA021115, ECOG-4697, SWOG-E4697, E4697, NCT00005034

Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 9018, UCCRC-9018, UCCRC-8381, NCI-G97-1162, NCT00002952

Phase I/II Study of Ad2/MART-1v2 and Ad2/gp100v2 Melanoma Antigen Vaccines in Patients With Stage II, III, or IV Melanoma (Summary Last Modified 07/2002). Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GENZ-ADVMEL-001-99, DFCI-00069, GENZ-2000-P-000380/1, NCT00010309

Phase II Study of Immunization Comprising Immunodominant Peptides from 3 Melanoma Antigens (MART-1, gp100, and Tyrosinase) in Patients With Refractory Metastatic Melanoma (Summary Last Modified 10/2000)

Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-98-C-0023, NCI-T97-0089, T97-0089

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: 990158, 99-C-0158, NCI-99-C-0158, NCI-T99-0078, T99-0078, NCT00019942, NCT00001832

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: CDR0000067391, NCI-99-C-0159, NCI-T99-0079, T99-0079, NCT00019994

Phase II Randomized Study of Immunization With an HLA-A2 Multiepitope Peptide Vaccine Comprising MART-1:27-35, gp100:209-217 (210M), and Tyrosinase:368-376 (370D) Peptides Alone or in Combination With Sargramostim (GM-CSF) and/or Interferon alfa-2b in HLA-A2 Positive Patients With Metastatic Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: E-1696, NCT00006385, E1696

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000069220 (10M-01-1), LAC-USC-10M011, LAC-USC-IRB-013030, NCI-5506, 5506, NCT00031733

Peptide Vaccination for Patients at High Risk for Recurrent Melanoma

Phase: Phase II
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor: NCI
Protocol IDs: 030172, 03-C-0172, NCI-03-C-0172, NCI-6211, 6211, NCT00062218, NCT00059475

10.

Phase II Randomized Study of Immunization With MAGE-3, Melan-A, gp100 Antigen, and NA17-A Peptide-Pulsed Autologous Peripheral Blood Mononuclear Cells and Interleukin-12 With or Without Low-Dose Interleukin-2 in Patients With Metastatic Melanoma

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCCRC-11447A, NCI-1330, NCT00064168, 1330

11.

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CDR0000365467, P30CA076292, P30CA014089, MCC-15241, MDX010-16, NCI-6446, CA184-016, 6446, LAC-USC-10M036, NCT00084656

12.

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02618, 10M-03-8, LAC-USC-042011, NCI-6618, LAC-USC-0A1033, CDR0000378033, LAC-USC-10M038, 6618, NCT00089063

13.

Phase II Study of Recombinant LMB-2 Immunotoxin and Peptide Vaccination Comprising gp100:209-217 (210M) Antigen, MART-1:27-35 Antigen, and Montanide ISA-51 in Patients With Progressive Unresectable Metastatic Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-06-C-0041, 7542, NCI-7542, NCI-P6702, NCT00295958

14.

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI, Other
Protocol IDs: 10M-03-1, LAC-USC-10M-03-1, NCI-6262, LAC-USC-033307, CDR0000480137, NCI-2009-00050, 6262, NCT00334776

15.

Phase I Study of Immunization with Recombinant Fowlpox Virus Encoding the MART-1 Melanoma Antigen with or without Concomitant IL-2 in Patients with Metastatic Melanoma (Summary Last Modified 01/00)

Phase: Phase I
Type: Treatment
Status: Completed
Age: over 18
Sponsor: NCI
Protocol IDs: NCI-95-C-0032D, NCI-T96-0026N, T96-0026

16.

Phase I Study of MART-1 Human Melanoma Peptide Vaccine in Metastatic Melanoma (Summary Last Modified 01/2000)

Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-95-C-0071C, NCI-T94-0178N, T94-0178

17.

Phase I Study of Immunization with Recombinant Vaccinia Virus Encoding the MART-1 Melanoma Antigen with or without Concomitant IL-2 in Patients with Metastatic Melanoma (Summary Last Modified 03/1999)

Phase: Phase I
Type: Treatment
Status: Completed
Age: over 18
Sponsor: NCI
Protocol IDs: NCI-95-C-0068C, NCI-T94-0137N, T94-0137

18.

Phase I Study of Immunization with Adenovirus Encoding the MART-1 Melanoma Antigen for Refractory Metastatic Melanoma (Summary Last Modified 12/1999)

Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-95-C-0079D, NCI-T94-0195N, T94-0195

19.

Phase I Study of IL-12 Administered with a MART-1 Peptide Vaccine in Patients with Refractory Metastatic Melanoma (Summary Last Modified 11/1999)

Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-95-C-0143B, NCI-T95-0039N, T95-0039

20.

Phase I Study of Vaccination with MART-1 Antigen in HLA-A2-Positive Patients with Resectable Stage IIB, III, or IV Melanoma (Summary Last Modified 11/1999)

Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: LAC-USC-10M954, NCI-T95-0069D, T95-0069

21.

Phase I/Ib Study of Tyrosinase/gp100/MART-1 Antigen Peptide Pulsed Dendritic Cell Vaccine for Metastatic Melanoma (Summary Last Modified 01/2000)

Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: LAC-USC-10M961, NCI-T96-0072, T96-0072

22.

Phase I Study of Dendritic Cell Immunotherapy in Patients With Metastatic Melanoma (Summary Last Modified 09/2000). Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 to 80
Sponsor: NCI
Protocol IDs: BAYUMC-098004, NCI-T98-0054, NCT00003792, T98-0054

23.

Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery

Phase: Phase I
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: CDR0000068934 (10M-00-4), LAC-USC-10M004, MDX-MDXCTLA4-03, NCI-4210, 4210, NCT00025181

24.

Phase I Pilot Randomized Study of Melanoma Peptide Vaccine With or Without Sargramostim (GM-CSF) in Patients With High-Risk or Metastatic Melanoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CPMC-IRB-13824, LUDWIG-LUD00-025, NCI-G02-2068, NCT00037037

25.

CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery

Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000380840, P30CA016042, UCLA-0312023, PFIZER-NRA3670003, NCT00090896

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map